Abstracts tagged "Lupus"

Abstract Number: 422 • 2015 ACR/ARHP Annual Meeting
Mood Disorder Is Highly Prevalent in a Multi-Ethnic Urban Pediatric Lupus Cohort
Tamar Rubinstein^1,2, Dawn Wahezi^1,2, Jay Mehta^3,4, Norman Ilowite^3,5, Debbie Rybak⁶, Jordan Brodsky⁶, Nicole Jordan⁶, Ruth Stein^5,7 and Chaim Putterman⁶, ¹Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Division of Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁴Division of Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁷Pediatrics, Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: While mood disorder, most commonly manifesting as depression and anxiety symptoms, is often reported in pediatric lupus patients, prevalence rates vary widely. Many published…
Abstract Number: 815 • 2015 ACR/ARHP Annual Meeting
Lys63-Polyubiquitination By the E3 Ligase Casitas B-Lineage Lymphoma-b Modulates Peripheral Regulatory T Cell Tolerance in Patients with Systemic Lupus Erythematosus
Diana Gómez-Martín¹, Jorge Alcocer-Varela¹, Jorge Romo-Tena¹, Ana Barrera-Vargas¹ and Javier Merayo-Chalico², ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The interplay between effector and regulatory T cells (Tregs) is a key element among peripheral tolerance mechanisms in Systemic Lupus Erythematosus (SLE). Resistance to…
Abstract Number: 1779 • 2015 ACR/ARHP Annual Meeting
Characterization of Anti-Nuclear Antibody (ANA) Signatures in Murine Models of Lupus Using Genalyte Maverick Technology
Jacqueline Loud¹, Stuart Perper², Rachel Twomey² and Stephen Clarke², ¹Immunology Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²Immunology Pharmacology, Abbvie Bioresearch Center Inc., Worcester, MA
Background/Purpose: Systemic lupus erythematosus (SLE) and lupus nephritis (LN) are autoimmune diseases characterized by circulating antibodies to nuclear self-antigens, including reactivities to double-stranded DNA, RNP…
Abstract Number: 2512 • 2015 ACR/ARHP Annual Meeting
Depot Medroxyprogesterone Acetate Birth Control May Suppress Toll-like Receptor 7-Induced Interferon-Alpha Production By Plasmacytoid Dendritic Cells in Women
Yuli McCann¹, Meredith Barnes¹ and Grant Hughes², ¹Medicine, University of Washington, Seattle, WA, ²Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Female sex steroids are important modulators of autoimmunity. Estrogen appears to favor the development of lupus autoimmunity via activation of adaptive and innate immune…
Abstract Number: 423 • 2015 ACR/ARHP Annual Meeting
Institutional and Regional Variation in Childhood SLE 30-Day Hospital Readmission Rates: A Comparative Effectiveness Research Using the Pediatric Health Information System Database
Breanna Beltz¹, Mohammad Shah², Mary Toth³ and Moussa El-Hallak⁴, ¹Hiram College, Akron, OH, ²Patient Safety and Quality Services, Akron Children's Hospital, Akron, OH, ³Rheumatology, Akron Children's Hospital, Akron, OH, ⁴Dept of Pediatric Rheumatology, Akron Children's Hospital, Akron, OH
Background/Purpose: Early hospital readmission is emerging as an indicator of care quality. The reported 30-day hospital readmission (30-DHR) rate for pediatric patients is 6.5%. However,…
Abstract Number: 932 • 2015 ACR/ARHP Annual Meeting
IRF4-Dependent and IRF4-Independent Pathways Contribute to DC Dysfunction in Lupus
Michela Manni¹, Sanjay Gupta², Briana G. Nixon³ and Alessandra B. Pernis⁴, ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ²Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY, ³Graduate Program in Immunology and Microbial Pathogenesis, Weill Cornell Graduate School of Medical Sciences, New York, NY, ⁴Autoimmunity & Inflammation, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Interferon Regulatory Factors (IRFs) play fundamental roles in dendritic cell (DC) differentiation and function. In particular IRFs are critical transducers of Toll-like Receptors (TLR)…
Abstract Number: 1786 • 2015 ACR/ARHP Annual Meeting
Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE
Vibeke Strand¹, Annette Diehl², Jared Christensen², Joseph Wajdula², Sudhakar Sridharan³ and Paul J Healey², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, New York City, NY, ³PPD Inc, Rockville, MA
Background/Purpose: The 10 mg dose of PF-04236921 showed evidence of efficacy in a phase 2 randomized controlled trial (RCT) in SLE.1,2 Here patient-reported outcomes (PROs)…
Abstract Number: 2529 • 2015 ACR/ARHP Annual Meeting
Decreased Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta
Gail Deutsch^1,2, Megan Yuasa³ and Anne M. Stevens^4,5, ¹Pathology, Seattle Children's Hospital, Seattle, WA, ²School of Medicine, University of Washington, Seattle, WA, ³Seattle Children's Res Institute, Seattle Children's Research Institute, Seattle, WA, ⁴Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, ⁵Pediatrics, University of Washington, Seattle, WA
Background/Purpose: The increased rates of preeclampsia, preterm birth, and intrauterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid…
Abstract Number: 741 • 2015 ACR/ARHP Annual Meeting
Satisfaction and Impact Associated with the Addition of Belimumab to Systemic Lupus Erythematosus (SLE) Treatment: A Cross-Sectional Survey of US Rheumatologists and Their Patients
Katie Pascoe¹, Steve Lobosco², David Bell³, Ben Hoskin³, Sulabha Ramachandran⁴, Bonnie Pobiner⁵ and David Chang⁶, ¹Value Evidence and Outcomes, GlaxoSmithKline, Uxbridge, United Kingdom, ²Adelphi Real World Ltd., Macclesfield, United Kingdom, ³Autoimmune, Adelphi Real World Ltd., Manchester, United Kingdom, ⁴Value Evidence and Outcomes, GlaxoSmithKline, Renaissance Centre, PA, ⁵Immuno-Inflammation Therapy Area, GlaxoSmithKline, Triangle Park, NC, ⁶US Medical Affairs, GlaxoSmithKline, Philadelphia, PA
Background/Purpose: Patient and physician treatment satisfaction influences long-term adherence with a treatment regimen. The primary objective was to identify factors linked to satisfaction with the…
Abstract Number: 987 • 2015 ACR/ARHP Annual Meeting
Pre-Emptive Renal Transplantation Among End Stage Renal Disease Patients with and without SLE
Anna R. Broder¹, Wenzhu Mowrey², Ladan Golestaneh³, Mimi Kim⁴, Karen H. Costenbader⁵ and Chaim Putterman⁶, ¹Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Department of Epidemiology and Population Health/Division of Biostatistics, Albert Einstein College of Medicine, Bronx, NY, ³Medicine/Nephrology, Albert Einstein College of Medicine, Bronx, NY, ⁴Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁵Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lack of evidence-based recommendations about pre-emptive renal transplantation in systemic lupus erythematosus (SLE) patients with end stage renal disease (ESRD) may be unnecessarily delaying…
Abstract Number: 1804 • 2015 ACR/ARHP Annual Meeting
Association of the Metabolic Syndrome (MetS) with Vascular Complications, End Stage Renal Failure (ESRF) and Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Cohort Analysis
Chi Chiu Mok¹, Kar Li Chan¹, Sau Mei Tse¹ and Ling Yin Ho², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To study the association between the metabolic syndrome (MetS) and vascular events, end stage renal failure (ESRF) and mortality in patients with SLEMethods: Patients…
Abstract Number: 2901 • 2015 ACR/ARHP Annual Meeting
Anti-dsDNA Antibodies Measured By Chemiluminescent Immunoassay Show Strong Association with Active Lupus Nephritis
Gabriella Lakos¹, John G. Hanly², Peter Martis¹, Chelsea Bentow¹, Milagros Garcia³, Odette Viñas³, Gerard Espinosa⁴, Ricard Cervera⁴ and Michael Mahler⁵, ¹Research, Inova Diagnostics, San Diego, CA, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Immunology, Hospital Clinic of Barcelona, Barcelona, Spain, ⁴Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain, ⁵Inova Diagnostics, San Diego, CA
Background/Purpose: Anti-dsDNA antibodies support the diagnosis of systemic lupus erythematosus (SLE), and their quantification is useful for the assessment of lupus nephritis (LN) and the…
Abstract Number: 750 • 2015 ACR/ARHP Annual Meeting
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and Meta-Analysis
Jasvinder A. Singh¹ and Nipam Shah², ¹University of Alabama at Birmingham, Birmingham, AL, ²University fo Alabama at Birmingham, Birmingham, AL
Background/Purpose: Belimumab is a new approved treatment option for patients with lupus. Our objective was to perform a systematic review of benefits and harms of…
Abstract Number: 992 • 2015 ACR/ARHP Annual Meeting
Therapeutic Targeting of CD4+ T Cell Metabolism in Murine Models of Lupus
Laurence Morel¹, Seung-Chul Choi², Zhiwei Xu², Elisabeth Adkins³, Byron Croker² and Derry Roopenian³, ¹Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, ²University of Florida, Gainesville, FL, ³The Jackson Laboratory, Bar Harbor, ME
Background/Purpose: Cellular metabolism controls T cell functions, with TCR-mediated activation enhancing metabolism, and substrate utilization modulating effector functions. Autoreactive CD4 T cells are key effectors…
Abstract Number: 1818 • 2015 ACR/ARHP Annual Meeting
Cyclophosphamide and Cumulative Steroid Dose Associated with Higher Risk of Infections in Patients with Lupus Nephritis
Shubhasree Dutta Choudhury¹, Ann Biehl², Maryam Ghaderi-yeganeh³, Zerai Manna⁴ and Sarfaraz Hasni⁴, ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases2, National Institutes of Health, Bethesda, MD, ²Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD, ³National Institutes of Health Clinical Center Department of Pharmacy, National Institutes of Health, Bethesa, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Immune dysregulation associated with SLE leads to a substantially high background risk of infection. This risk of infection further increases with the use of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.